

# Sandra Rebouissou

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7270721/publications.pdf>

Version: 2024-02-01

48  
papers

9,002  
citations

109137

35  
h-index

205818

48  
g-index

50  
all docs

50  
docs citations

50  
times ranked

10758  
citing authors

#	ARTICLE	IF	CITATIONS
1	Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. <i>Nature Genetics</i> , 2015, 47, 505-511.	9.4	1,372
2	Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. <i>Hepatology</i> , 2007, 45, 42-52.	3.6	1,034
3	Genotype-phenotype correlation in hepatocellular adenoma: New classification and relationship with HCC. <i>Hepatology</i> , 2006, 43, 515-524.	3.6	733
4	MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. <i>Hepatology</i> , 2008, 47, 1955-1963.	3.6	634
5	Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. <i>Hepatology</i> , 2007, 46, 740-748.	3.6	554
6	Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. <i>Nature</i> , 2009, 457, 200-204.	13.7	437
7	Advances in molecular classification and precision oncology in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 72, 215-229.	1.8	311
8	EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. <i>Science Translational Medicine</i> , 2014, 6, 244ra91.	5.8	304
9	A Hepatocellular Carcinoma 5-Gene Score Associated With Survival of Patients After Liver Resection. <i>Gastroenterology</i> , 2013, 145, 176-187.	0.6	302
10	Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation. <i>Gastroenterology</i> , 2017, 152, 880-894.e6.	0.6	290
11	Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma. <i>Journal of Hepatology</i> , 2008, 48, 163-170.	1.8	235
12	Genotype-phenotype correlation of CTNNB1 mutations reveals different Wnt/catenin activity associated with liver tumor progression. <i>Hepatology</i> , 2016, 64, 2047-2061.	3.6	222
13	Clinical, Morphologic, and Molecular Features Defining So-Called Telangiectatic Focal Nodular Hyperplasias of the Liver. <i>Gastroenterology</i> , 2005, 128, 1211-1218.	0.6	207
14	Independent Component Analysis Uncovers the Landscape of the Bladder Tumor Transcriptome and Reveals Insights into Luminal and Basal Subtypes. <i>Cell Reports</i> , 2014, 9, 1235-1245.	2.9	181
15	The role of telomeres and telomerase in cirrhosis and liver cancer. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 544-558.	8.2	154
16	Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type I. <i>Journal of Hepatology</i> , 2013, 58, 350-357.	1.8	146
17	Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response. <i>Gastroenterology</i> , 2019, 157, 760-776.	0.6	141
18	Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma. <i>Hepatology</i> , 2020, 71, 164-182.	3.6	129

#	ARTICLE	IF	CITATIONS
19	Clinical and molecular analysis of combined hepatocellular-cholangiocarcinomas. <i>Journal of Hepatology</i> , 2004, 41, 292-298.	1.8	126
20	HNF1 $\alpha$ Inactivation Promotes Lipogenesis in Human Hepatocellular Adenoma Independently of SREBP-1 and Carbohydrate-response Element-binding Protein (ChREBP) Activation. <i>Journal of Biological Chemistry</i> , 2007, 282, 14437-14446.	1.6	123
21	Germline hepatocyte nuclear factor 1 $\alpha$ and 1 $\beta$ mutations in renal cell carcinomas. <i>Human Molecular Genetics</i> , 2005, 14, 603-614.	1.4	109
22	A Modeling Approach to Explain Mutually Exclusive and Co-Occurring Genetic Alterations in Bladder Tumorigenesis. <i>Cancer Research</i> , 2015, 75, 4042-4052.	0.4	96
23	Inhibiting Glutamine-Dependent mTORC1 Activation Ameliorates Liver Cancers Driven by $\beta$ -Catenin Mutations. <i>Cell Metabolism</i> , 2019, 29, 1135-1150.e6.	7.2	92
24	Childhood leukaemia, polymorphisms of metabolism enzyme genes, and interactions with maternal tobacco, coffee and alcohol consumption during pregnancy. <i>European Journal of Cancer Prevention</i> , 2005, 14, 531-540.	0.6	91
25	<i>CDKN2A</i> homozygous deletion is associated with muscle invasion in <i>FGFR3</i> -mutated urothelial bladder carcinoma. <i>Journal of Pathology</i> , 2012, 227, 315-324.	2.1	90
26	Genotype phenotype classification of hepatocellular adenoma. <i>World Journal of Gastroenterology</i> , 2007, 13, 2649.	1.4	90
27	The $\beta$ -catenin pathway is activated in focal nodular hyperplasia but not in cirrhotic FNH-like nodules. <i>Journal of Hepatology</i> , 2008, 49, 61-71.	1.8	87
28	Dual Targeting of Histone Methyltransferase G9a and DNA Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 69, 587-603.	3.6	81
29	PI3K/AKT pathway activation in bladder carcinogenesis. <i>International Journal of Cancer</i> , 2014, 134, 1776-1784.	2.3	74
30	Loss of hepatocyte nuclear factor 1 $\alpha$ function in human hepatocellular adenomas leads to aberrant activation of signaling pathways involved in tumorigenesis. <i>Hepatology</i> , 2010, 51, 557-566.	3.6	66
31	Proliferation Markers Are Associated with MET Expression in Hepatocellular Carcinoma and Predict Tivantinib Sensitivity <i>In Vitro</i> . <i>Clinical Cancer Research</i> , 2017, 23, 4364-4375.	3.2	57
32	Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target. <i>Journal of Hepatology</i> , 2021, 74, 1155-1166.	1.8	54
33	Recurrent activating mutations of PPAR $\gamma$ associated with luminal bladder tumors. <i>Nature Communications</i> , 2019, 10, 253.	5.8	44
34	Argininosuccinate synthase 1 and periportal gene expression in sonic hedgehog hepatocellular adenomas. <i>Hepatology</i> , 2018, 68, 964-976.	3.6	43
35	Integrated Genomic Analysis Identifies Driver Genes and Cisplatin-Resistant Progenitor Phenotype in Pediatric Liver Cancer. <i>Cancer Discovery</i> , 2021, 11, 2524-2543.	7.7	41
36	Note of caution: Contaminations of hepatocellular cell lines. <i>Journal of Hepatology</i> , 2017, 67, 896-897.	1.8	37

#	ARTICLE	IF	CITATIONS
37	Common genetic variation in alcohol-related hepatocellular carcinoma: a case-control genome-wide association study. <i>Lancet Oncology</i> , The, 2022, 23, 161-171.	5.1	36
38	HNF1 $\beta$ inhibition triggers epithelial-mesenchymal transition in human liver cancer cell lines. <i>BMC Cancer</i> , 2011, 11, 427.	1.1	35
39	Mutation of TP53 gene is involved in carcinogenesis of hepatic undifferentiated (embryonal) sarcoma of the adult, in contrast with Wnt or telomerase pathways: an immunohistochemical study of three cases with genomic relation in two cases. <i>Journal of Hepatology</i> , 2005, 42, 424-429.	1.8	32
40	<i>APC</i> germline hepatoblastomas demonstrate cisplatin-induced intratumor tertiary lymphoid structures. <i>Oncolmmunology</i> , 2019, 8, e1583547.	2.1	31
41	Mutation of TCF1 encoding hepatocyte nuclear factor 1 $\beta$ in gynecological cancer. <i>Oncogene</i> , 2004, 23, 7588-7592.	2.6	21
42	NRF2/KEAP1 and Wnt/ $\beta$ -catenin in the multistep process of liver carcinogenesis in humans and rats. <i>Hepatology</i> , 2015, 62, 677-679.	3.6	20
43	Recurrent chromosomal rearrangements of <i>ROS1</i> , <i>FRK</i> and <i>IL6</i> activating JAK/STAT pathway in inflammatory hepatocellular adenomas. <i>Gut</i> , 2020, 69, 1667-1676.	6.1	17
44	A phosphokinomeâ€¢based screen uncovers new drug synergies for cancer driven by liverâ€¢specific gain of nononcogenic receptor tyrosine kinases. <i>Hepatology</i> , 2017, 66, 1644-1661.	3.6	15
45	Sigma 1 Receptor is Overexpressed in Hepatocellular Adenoma: Involvement of ER $\alpha$ and HNF1 $\beta$ . <i>Cancers</i> , 2020, 12, 2213.	1.7	4
46	Identification of targeted therapy for an aggressive subgroup of muscle-invasive bladder cancers. <i>Molecular and Cellular Oncology</i> , 2015, 2, e999507.	0.3	1
47	Reply. <i>Hepatology</i> , 2017, 66, 2093-2094.	3.6	1
48	Abstract 2973: Exome sequencing of 243 liver tumors identifies new mutational signatures and potential therapeutic targets. , 2015, , .		0